Table 2.
Distribution of the clinicopathologic characteristics stratified by group in Group Lobe (n = 1,292).
| Characteristic | Total | Group A (n = 346) | Group B (n = 328) | Group C (n = 577) | Group D (n = 13) | Group E (n = 28) | P |
|---|---|---|---|---|---|---|---|
| Sex | 0.361 | ||||||
| Male | 822(63.6) | 233(67.3) | 204(62.3) | 359(62.2) | 10(76.9) | 16(57.1) | |
| Female | 470(36.4) | 113(32.7) | 124(37.7) | 218(37.8) | 3(23.1) | 12(42.9) | |
| Age(years) | <0.001 | ||||||
| Mean ± SD | 59.35 ± 10.1 | 59.99 ± 10.7 | 58.96 ± 9.8 | 58.94 ± 10.0 | 73.77 ± 6.4 | 58.86 ± 7.5 | |
| Median(min, max) | 60(16, 84) | 61(23, 84) | 59(32, 80) | 60(16, 80) | 76(61, 84) | 59.5(46, 74) | |
| Year of procedure | <0.001 | ||||||
| 1999–2002 | 78(6.0) | 43(12.4) | 5(1.8) | 26(4.5) | 4(30.8) | 0 | |
| 2003–2006 | 155(12.0) | 76(22.0) | 25(7.6) | 51(8.8) | 3(23.1) | 0 | |
| 2007–2010 | 372(28.8) | 122(35.3) | 77(23.4) | 166(28.8) | 4(30.8) | 3(10.7) | |
| 2011–2014 | 687(53.2) | 105(30.3) | 221(67.2) | 334(57.9) | 2(15.4) | 25(89.3) | |
| Histology | 0.061 | ||||||
| Non-squamous cell carcinoma | 1002(77.6) | 267(77.2) | 239(72.9) | 462(80.1) | 9(69.2) | 25(89.3) | |
| Squamous cell carcinoma | 290(22.4) | 79(22.8) | 89(27.1) | 115(19.9) | 4(30.8) | 3(10.7) | |
| Cell differentiation | 0.797 | ||||||
| Poor–None | 468 | 121(35.0) | 126(38.3) | 204(35.4) | 5(38.5) | 12(42.9) | |
| Well–Moderate | 824 | 225(65.0) | 202(61.7) | 373(64.6) | 8(61.5) | 16(57.1) | |
| Tumor size (cm) | 0.067 | ||||||
| Mean ± SD | 2.67 ± 1.0 | 2.77 ± 1.0 | 2.7 ± 1.0 | 2.59 ± 0.9 | 2.69 ± 1.0 | 2.61 ± 1.0 | |
| Median(min, max) | 2(0, 4) | 3(0, 4) | 3(1, 4) | 2(0, 4) | 2(1, 4) | 2(1, 4) | |
| Smoking history | 0.730 | ||||||
| Yes | 503(38.9) | 140(40.5) | 133(40.7) | 217(37.6) | 4(30.8) | 9(32.1) | |
| No | 789(61.1) | 206(59.5) | 195(59.3) | 360(62.4) | 9(69.2) | 19(67.9) | |
| Pathological T category | 0.002 | ||||||
| T1a | 57(4.3) | 10(2.9) | 20(6.1) | 26(4.3) | 0 | 1(3.6) | |
| T1b | 228(17.7) | 48(13.9) | 52(15.9) | 122(21.1) | 0 | 6(21.4) | |
| T1c | 204(15.8) | 42(12.1) | 67(20.4) | 89(15.4) | 1(7.7) | 5(17.9) | |
| T2a | 803(62.2) | 246(71.1) | 188(57.6) | 341(59.1) | 12(92.3) | 16(57.1) | |
| Pathological stage | 0.002 | ||||||
| I A1 | 57(4.3) | 10(2.9) | 20(6.1) | 26(4.3) | 0 | 1(3.6) | |
| I A2 | 228(17.7) | 48(13.9) | 52(15.9) | 122(21.1) | 0 | 6(21.4) | |
| I A3 | 204(15.8) | 42(12.1) | 67(20.4) | 89(15.4) | 1(7.7) | 5(17.9) | |
| I B | 803(62.2) | 246(71.1) | 188(57.6) | 341(59.1) | 12(92.3) | 16(57.1) | |
| Adjuvant therapy | 0.202 | ||||||
| Yes | 188(14.6) | 58(16.8) | 41(12.5) | 85(14.7) | 4(30.8) | 1(3.6) | |
| No | 1104(85.4) | 288(83.2) | 287(87.5) | 492(85.3) | 9(69.2) | 27(96.4) | |
| Tumor location | <0.001 | ||||||
| LUL | 341(26.4) | 101(29.2) | 84(25.5) | 139(24.1) | 5(38.5) | 12(42.9) | |
| LLL | 180(13.9) | 73(20.8) | 43(13.1) | 59(10.2) | 0 | 6(21.4) | |
| LL | 8(0.6) | 0 | 4(1.2) | 4(0.7) | 0 | 0 | |
| RUL | 416(32.2) | 59(17.1) | 119(36.5) | 229(19.7) | 1(7.7) | 8(28.6) | |
| RML | 116(9.0) | 22(6.4) | 12(3.6) | 78(13.5) | 3(23.1) | 1(3.6) | |
| RLL | 220(17.0) | 89(25.7) | 60(18.2) | 66(11.4) | 4(30.8) | 1(3.6) | |
| RUML | 2(0.1) | 1(0.3) | 1(0.3) | 0 | 0 | 0 | |
| RMLL | 8(0.6) | 2(0.6) | 4(1.2) | 2(0.3) | 0 | 0 | |
| RL | 1(0.1) | 0 | 1(0.3) | 0 | 0 | 0 | |
| Surgical approach | 0.089 | ||||||
| Lobectomy | 1234(95.5) | 334(96.5) | 308(93.9) | 552(95.7) | 13(100.0) | 27(96.4) | |
| Biolobectomy | 33(2.6) | 9(2.6) | 15(4.6) | 9(1.6) | 0 | 0 | |
| Pneumonectomy | 25(1.9) | 3(0.9) | 5(1.5) | 16(2.8) | 0 | 1(3.6) | |
| Number of lymph nodes resected | <0.001 | ||||||
| Mean ± SD | 18.49 ± 11.0 | 11.66 ± 6.9 | 25.02 ± 10.2 | 18.09 ± 8.5 | 0 | 42.71 ± 21.3 | |
| Median(min, max) | 17(0, 125) | 10(1, 43) | 23(7, 79) | 17(3, 57) | 0 | 39(9, 125) | |
| Treatment after progression of disease | 0.506 | ||||||
| Yes | 191(14.8) | 54(15.6) | 47(14.3) | 83(14.4) | 4(30.8) | 3(10.7) | |
| No | 1101(85.2) | 292(84.4) | 281(85.7) | 494(85.6) | 9(69.2) | 25(89.3) | |
| EGFR mutation | <0.001 | ||||||
| Negative | 228(17.6) | 41(11.8) | 75(22.8) | 107(18.5) | 1(7.7) | 4(14.3) | |
| Positive | 209(16.2) | 34(15.5) | 53(24.2) | 111(19.2) | 0 | 11(39.3) | |
| Not tested | 855(66.2) | 271(78.3) | 200(61.1) | 359(62.2) | 12(92.3) | 13(46.4) | |
| ALK mutation | <0.001 | ||||||
| Negative | 295(22.8) | 44(12.7) | 83(25.2) | 156(27.0) | 0 | 12(42.9) | |
| Positive | 9(0.7) | 2(0.6) | 2(0.6) | 5(0.9) | 0 | 0 | |
| Not tested | 988(76.5) | 300(86.7) | 243(72.1) | 416(72.1) | 13(100.0) | 16(57.1) |
ALK, anaplastic lymphoma kinase; cm, centimeter; EGFR, epidermal growth factor receptor; LUL, left upper lobe; LLL, left lower lobe; LL, left lung; max, maximum; min, minimum; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; RUML, right upper-middle lobe; RMLL, right middle-lower lobe; RL, right lung; SD, standard deviation.